AU2019203815A1 — Oral Composition of Celecoxib For Treatment of Pain
Assigned to Dr Reddys Laboratories Ltd · Expires 2019-06-20 · 7y expired
What this patent protects
The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted- State Simulated Ga…
USPTO Abstract
The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted- State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37°C 0.5°C and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib. . . . . . . . . A sr h~~F1 I~~( WO 2016/191744 PCT/US2016/034844 I Glycerine (7) 0,736 h |D 50,, 250 0,200 0,000 c 0,736 d 0 0936 B" Ethanol (7) A' Base composition(K) Overlay Plot FIG, I
Drugs covered by this patent
- Celebrex (celecoxib) · Pfizer Inc. (originally Searle/Pharmacia)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.